(Q50186375)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

title

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

5

Paul Dent

1 reference

PubMed publication ID

26 February 2018

Laurence Booth

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Jane L Roberts

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

John Kirkwood

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Andrew Poklepovic

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Paul Dent

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

3 January 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

Advances in Cancer Research

14 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

volume

137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

1-15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation

14 March 2020

cites work

1 reference

12 December 2020

Stat3 dimerization regulated by reversible acetylation of a single lysine residue

1 reference

12 December 2020

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

1 reference

12 December 2020

Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation

1 reference

12 December 2020

Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo

1 reference

12 December 2020

Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells

1 reference

12 December 2020

HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells

1 reference

12 December 2020

HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling

1 reference

12 December 2020

Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.

1 reference

12 December 2020

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

1 reference

12 December 2020

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

1 reference

12 December 2020

Post-translational modifications of Hsp90 and their contributions to chaperone regulation

1 reference

12 December 2020

Epigenetic regulation of canonical TNFα pathway by HDAC1 determines survival of cardiac myocytes.

1 reference

12 December 2020

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors

1 reference

12 December 2020

Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes

1 reference

12 December 2020

New and emerging HDAC inhibitors for cancer treatment

1 reference

12 December 2020

HDAC6: physiological function and its selective inhibitors for cancer treatment

1 reference

12 December 2020

Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.

1 reference

12 December 2020

Blocking NF-κB sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.

1 reference

12 December 2020

Chaperone-mediated 26S proteasome remodeling facilitates free K63 ubiquitin chain production and aggresome clearance

1 reference

12 December 2020

Hsp90 inhibition induces both protein-specific and global changes in the ubiquitinome.

1 reference

12 December 2020

KRAS as a Therapeutic Target

1 reference

12 December 2020

Sp3/REST/HDAC1/HDAC2 Complex Represses and Sp1/HIF-1/p300 Complex Activates ncx1 Gene Transcription, in Brain Ischemia and in Ischemic Brain Preconditioning, by Epigenetic Mechanism.

1 reference

12 December 2020

Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer

1 reference

12 December 2020

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

1 reference

12 December 2020

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.

1 reference

12 December 2020

Histone deacetylase inhibitors as immunomodulators in cancer therapeutics

1 reference

12 December 2020

PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations

1 reference

12 December 2020

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

1 reference

12 December 2020

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling

1 reference

12 December 2020

Beyond the Selective Inhibition of Histone Deacetylase 6.

1 reference

12 December 2020

Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors

1 reference

12 December 2020

Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation

1 reference

12 December 2020

HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?

1 reference

12 December 2020

Acetylation modification regulates GRP78 secretion in colon cancer cells

1 reference

12 December 2020

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma

1 reference

12 December 2020

Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma

1 reference

12 December 2020

Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines

1 reference

12 December 2020

Malignant melanoma-The cradle of anti-neoplastic immunotherapy

1 reference

12 December 2020

Acetylation of androgen receptor by ARD1 promotes dissociation from HSP90 complex and prostate tumorigenesis.

1 reference

12 December 2020

ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding and degradation

1 reference

12 December 2020

Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside

1 reference

12 December 2020

Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016).

1 reference

12 December 2020

Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.

1 reference

12 December 2020

RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers

1 reference

12 December 2020

Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives

1 reference

12 December 2020

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide

1 reference

12 December 2020

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo

1 reference

12 December 2020

Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma

1 reference

12 December 2020

The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.

1 reference

12 December 2020

Immune Checkpoint in Glioblastoma: Promising and Challenging

1 reference

12 December 2020

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

1 reference

12 December 2020

Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma

1 reference

12 December 2020

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

1 reference

12 December 2020

Hsp70 acetylation prevents caspase-dependent/independent apoptosis and autophagic cell death in cancer cells.

1 reference

12 December 2020

Rationale for immunological approaches to breast cancer therapy

1 reference

12 December 2020

Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells

1 reference

12 December 2020

[pemetrexed + sildenafil], via autophagy-dependent HDAC down-regulation, enhances the immunotherapy response of NSCLC cells

1 reference

12 December 2020

Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review

1 reference

12 December 2020

Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma

1 reference

12 December 2020

HDAC inhibitors enhance the immunotherapy response of melanoma cells

1 reference

12 December 2020

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

1 reference

12 December 2020

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

1 reference

12 December 2020

10.1016/BS.ACR.2017.11.004

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29405973%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

PubMed publication ID

29405973

1 reference